Showing 8381-8390 of 8687 results for "".
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- New Fractionated Skin Resurfacing Module Enhances RF Laser Treatmentshttps://practicaldermatology.com/news/20121017-new_fractionated_skin_resurfacing_module_shortens_rf_laser_treatments/2459704/The PixelRF fractionated skin resurfacing module from Alma Lasers, Inc. uses proprietary InMotion Refractive Radiofrequency Micro Plasma Technology, which both ablates and heats the skin through controlled, focused delivery of energy without using disposables. The PixelRF was recently added to Alma'
- Restoration Robotics, Inc. Appoints Cary Rayment to Board of Directorshttps://practicaldermatology.com/news/20121015-restoration_robotics_inc_appoints_cary_rayment_to_board_of_directors/2459706/Cary Rayment joined the Board of Directors of Restoration Robotics, Inc.. He previously served as President and Chief Executive Officer of Alcon, Inc. until 2009 and then as non-executive chairman and director of Alcon, Inc.
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- ISHRS Kicks Off 20th Anniversaryhttps://practicaldermatology.com/news/20121003-ishrs_kicks_off_20th_anniversary/2459716/The International Society of Hair Restoration Surgery kicks off its 20th Anniversary this month. The ISHRS Annual Scientific Meeting is October 17-20 at Atlantis, Paradise Island, the Bahamas. The society is highlighting follicular units in hair res
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod